This past week, a dear family member, an older adult, found that she has COVID-19. After her husband was diagnosed and hospitalized, she got tested and was shocked to find herself positive. She immediately called her primary care physician he did not send her immediately for any treatment such as a monoclonal antibody. In fact,
Details

The year is 2021 and it is late spring. With COVID-19 vaccine quantities bountiful, you return to your preferred clinic after a year-long absence to receive the first of your two injections. In the small sterile office, it feels like you and your health care provider are the only ones in the room, a simple
Details

As the world waits for COVID-19 vaccines to become widely available, Amarin experiences a different form of anticipation, one which will see the fate of its own profitability. Our previous blog post on Amarin highlighted the disastrous effects of a U.S Court of Appeals decision to invalidate Amarin’s six patents. To briefly recap, while the
Details

Image from the StarTribune. https://www.startribune.com/u-of-m-nurse-practitioner-clinic-aims-to-help-fill-doctor-void/297468881/ After heading into a clinic and filling out the required forms, the assistant calls you back. “Wait in room number two,” the assistant says. Once there, a medical assistant enters and takes your vitals, leaving you with the confidence a qualified person will see you soon. A short while later,
Details

Image from Newsday. https://www.newsday.com/opinion/editorial/cure-vaccine-immunity-coronavirus-covid-19-rush-trump-science-1.48679327 With everyone is rushing to return pre-pandemic society, it is becoming clear that a vaccine is the only way to truly get there. Anxiously, the world waits on a vaccine for COVID-19 to get us back to work, back to school, back to play, and back to basic human connection. In
Details

Mergers and acquisitions are a hot topic in the biopharmaceutical industry. With 2019 setting records in terms of deal value and volume for biopharmaceutical M&A, many question the purpose of these processes. In addition to increasing shareholder value, management pursues mergers and acquisitions for a variety of reasons including innovation, synergy, and portfolio realignment. In
Details

In a relatively quick ruling, one that Amarin expected to occur in Q4 at the earliest, the U.S Court of Appeals for the Federal Circuit in Washington invalidated Amarin’s six patents. Essentially, this upheld the decision by the U.S District Court for the District of Nevada that Amarin’s patents for Vascepa, were a variation of
Details

Time is ticking! Need to optimize the value of a new therapy before generics are available. How can we extend the patent? These are all top of mind when developing, commercializing and managing the life cycle of a therapy. Unless engaged heavily in government affairs, it is easy to miss that this is all guided
Details

In a recent interview with Fox News host Chris Wallace, US President Donald Trump discussed his success taking the Montreal Cognitive Assessment (MoCA). The President appeared quite proud to have achieved a perfect score. He then questioned whether Wallace himself could answer the last five questions on the exam noting their difficulty. I was instantly
Details

We all know one size never fits all, yet, for the vast majority of medical history, care providers have been using that approach. Fortunately, with the advances in molecular and genetic medicine, precision medicine has become a viable alternative to the outdated and inefficient one-size-fits-all approach. Precision medicine, as the name suggests, does not concern
Details